Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 8/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30510268 | 1.00 | PPIA (0.34) | PPIAMEN1KMT2AITGB1ITGA4 | |
| SCHEMBL27215385 | 0.89 | PPIA (0.41) | PPIAMEN1KMT2AITGB1ITGA4 | |
| SCHEMBL25186515 | 0.89 | PPIA (0.41) | PPIAMEN1KMT2AITGB1ITGA4 | |
| SCHEMBL30510418 | 0.88 | PPIA (0.37) | PPIAKMT2AITGB1ITGA4CYP1A2 | |
| SCHEMBL5407004 | 0.84 | CTRB1 (0.40) | ITGB1ITGA4CYP1A2TSHRPPARG | |
| SCHEMBL4600752 | 0.84 | CTRB1 (0.40) | ITGB1ITGA4CYP1A2TSHRPPARG | |
| SCHEMBL30510366 | 0.84 | CTRB1 (0.40) | ITGB1ITGA4CYP1A2TSHRPPARG | |
| SCHEMBL4600067 | 0.84 | CTRB1 (0.40) | ITGB1ITGA4CYP1A2TSHRPPARG | |
| SCHEMBL25185914 | 0.84 | ITGB1 (0.39) | ITGB1ITGA4PPARGPPARACTRB1 | |
| SCHEMBL25186573 | 0.84 | SLC1A1 (0.41) | MEN1KMT2ACYP1A2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | PPIA 749/4885MEN1 492/4885KMT2A 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.